The holy grail of in vitro drug discovery is better clinical predictivity than in vivo animal studies, both to reduce/eliminate them and to improve clinical trial success rates.1,2 With Vala’s cardiac Kinetic Image Cytometry® high content screening platform, this holy grail is within reach.
Drug candidates for all indications often fail because preclinical animal studies do not accurately predict drug-induced human cardiotoxicity. Cardiac arrhythmia and cardiomyopathy side effects also dominate post-marketing drug withdrawals.3,4
Drug discovery for cardiac conditions suffers from similar failures. Heart failure drug candidates predicted to improve life expectancy based on animal studies have instead often reduced survival.5 Many antiarrhythmic drugs have narrow therapeutic windows, and off-target proarrhythmic effects limit their clinical use.6 Increasing the accuracy of preclinical in vitro drug discovery screens will drive the development of safer and more effective therapies.
Kinetic Image Cytometry® (KIC®) is the first and only in vitro preclinical screening system to exceed animal study predictivity for any indication. KIC® has been featured in four FDA Investigational New Drug (IND) applications by pharmaceutical partners for whom Vala has screened >1,200 compounds on hiPSC-cardiomyocytes.
Along with our partners, Vala uses KIC® of hiPSC-cardiomyocyte and adult cardiomyocyte models to predict drug toxicity in humans, to identify new drug targets and mechanisms of action for cardiac diseases, and to develop safer and more effective drug candidates.